I wonder what these results might mean for Acadia to press ahead with the trials of NNZ2591 for Fragile X syndrome as a matter of priority. Or are they already working at maximum speed on that application? The last investor presentation that referred to those trials indicated that Acadia were at Ph I stage of trialling 2591 for Fragile X (pg 6of 30 in presentation of 8th Nov). But there was no detail given in that presentation of whether the trial has actually started or when results were expected to be reported. Does anyone else have any more information about those trials by Acadia of 2591?
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-132
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.80 |
Change
-0.140(0.70%) |
Mkt cap ! $2.524B | |||
| Open | High | Low | Value | Volume |
| $19.95 | $19.97 | $19.50 | $5.098M | 256.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 136 | $19.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.80 | 311 | 11 |
View Market Depth
| Last trade - 14.45pm 20/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |